Keyruda for gastric and GE junction cancer – pro
yembrolizumab is approved to treat gastric cancer or gastroesophageal (GE) junction cancer that is recurrent and either locally advanced or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after two or more types of treatment including a fluoropyrimidine and platinum chemotherapy and, in some cases, HER2/neu targeted therapy. Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy.
Elizabeth C Smyth, David Cunningham, Encouraging results for PD-1 inhibition in gastric cancer. Lancet Oncoogy,
Volume 17, ISSUE 6, P682-683, June 01, 2016
Prescribing Information, Keytruda 2019
SD Kamath et al, Pembrolizumab for the treatment of gastric cancer. Expert Review of Anticancer Therapy 18(302):1-11 · October 2018